LabCorp to acquire clinical trials firm Chiltern for $1.2bn
The transaction will help LabCorp create leading expertise in the oncology segment by combining the extensive experience of Covance in late phase with the deep expertise of Chiltern
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an orally bioavailable neuroplastogen.